SCHEMBL3045573

SCHEMBL3045573

Cc1c(Br)csc1C(=O)Cl

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 11/20 0.44
GSK3B P49841 4/20 0.42
POLB P06746 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12261076 0.80 GPR35 (0.46) GPR35GSK3BPOLBTDP1L3MBTL1
SCHEMBL321098 0.80 GPR35 (0.60) GPR35GSK3BPOLBTDP1L3MBTL1
SCHEMBL7810682 0.80 GSK3B (0.41) GPR35GSK3BPOLBTDP1L3MBTL1
SCHEMBL1629386 0.78 GPR35 (0.44) GPR35GSK3B
SCHEMBL27447830 0.77 GSK3B (0.61) GPR35GSK3BCES2CES1
SCHEMBL14463157 0.77 GSK3B (0.39) GPR35GSK3BPOLBTDP1L3MBTL1
SCHEMBL16046036 0.76 GSK3B (0.44) GPR35GSK3BPOLBCES2CES1
SCHEMBL1529989 0.75 MAPT (0.46) GPR35POLBTDP1KMT2A
SCHEMBL12261073 0.75 GPR35 (0.42) GPR35GSK3BPOLB
SCHEMBL8306941 0.74 F10 (0.41) GPR35GSK3BPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150184307-A1 SILVER ELECTROPLATING SOLUTION DAIWA FINE CHEMICALS CO., LTD. (LABORATORY) (JP) 2015-07-02 US disclosed
EP-2881497-A1 ELECTROSILVER PLATING FLUID Daiwa Fine Chemicals Co., Ltd. (JP) 2015-06-10 EP disclosed
US-8541406-B2 Thiadiazole derivatives for the treatment of neurodegenerative diseases NV REMYND (BE) 2013-09-24 US disclosed
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2010-10-14 US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 US disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 US disclosed
US-20070284258-A1 Method For Silver Plating DAIWA FINE CHEMICALS CO., LTD. (JP) 2007-12-13 US disclosed
EP-1123291-B1 PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN DOW AGROSCIENCES LLC (US) 2007-07-18 EP disclosed
EP-1123291-B1 PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN DOW AGROSCIENCES LLC (US) 2007-07-18 EP disclosed
EP-1123290-B1 3-(SUBSTITUTED PHENYL)-5-THIENYL-1,2,4-TRIAZOLE COMPOUNDS WITH ACTIVITY AGAINST WHITEFLY DOW AGROSCIENCES LLC (US) 2003-02-19 EP disclosed
US-6329528-B1 REACTING ALKYL BENZTHIOIMIDATE OR ITS ACID ADDITION SALT WITH FURAN OR THIOFURAN ACID CHLORIDE COMPOUND TO PRODUCT ADDUCT-INTERMEDIATE; REACTING WITH METHYLHYDRAZINE TO PRODUCE 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES DOW AGROSCIENCES LLC 2001-12-11 US disclosed
EP-1123291-A1 PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN Dow Agrosciences LLC (US) 2001-08-16 EP disclosed
EP-1123290-A1 3-(SUBSTITUTED PHENYL)-5-THIENYL-1,2,4-TRIAZOLE COMPOUNDS WITH ACTIVITY AGAINST WHITEFLY Dow AgroSciences LLC (US) 2001-08-16 EP disclosed
US-6265424-B1 INSECTICIDES, MITICIDES DOW AGROSCIENCES LLC 2001-07-24 US disclosed
WO-2000024738-A1 PROCESS FOR PREPARING 3-(SUBSTITUTED PHENYL)-5-THIENYL OR FURYL)-1,2,4-TRIAZOLES AND NOVEL INTERMEDIATES UTILIZED THEREIN DOW AGROSCIENCES LLC (US) 2000-05-04 WO disclosed
WO-2000024737-A1 3-(SUBSTITUTED PHENYL)-5-THIENYL-1,2,4-TRIAZOLE COMPOUNDS WITH ACTIVITY AGAINST WHITEFLY DOW AGROSCIENCES LLC (US) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 GPR35 923/4885GSK3B 175/4885POLB 3933/4885
US-20100261707-A9 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 GPR35 923/4885GSK3B 175/4885POLB 3933/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 GPR35 923/4885GSK3B 175/4885POLB 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.